Liminatus Pharma faces potential Nasdaq delisting after failing $1 minimum bid price rule

• Nasdaq notified Liminatus Pharma on July 20, 2026 it remains below the $1 minimum bid price requirement under Listing Rule 5450(a)(1).
• Nasdaq said the company is not eligible for a second 180-day compliance extension; the Nasdaq Hearings Panel will weigh the deficiency.
• The panel has not issued a continued-listing decision; a written response is due by July 27, 2026.
• A reverse stock split vote is scheduled for Aug. 3, 2026, following a definitive proxy filing on July 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-086674), on July 24, 2026, and is solely responsible for the information contained therein.